U.S. markets open in 7 hours 5 minutes
  • S&P Futures

    4,220.00
    +10.00 (+0.24%)
     
  • Dow Futures

    33,338.00
    +78.00 (+0.23%)
     
  • Nasdaq Futures

    13,435.50
    +43.50 (+0.32%)
     
  • Russell 2000 Futures

    1,974.00
    +4.50 (+0.23%)
     
  • Crude Oil

    91.75
    -0.18 (-0.20%)
     
  • Gold

    1,801.20
    -12.50 (-0.69%)
     
  • Silver

    20.45
    -0.29 (-1.38%)
     
  • EUR/USD

    1.0304
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    2.7860
    0.0000 (0.00%)
     
  • Vix

    19.74
    -2.03 (-9.32%)
     
  • GBP/USD

    1.2215
    -0.0003 (-0.03%)
     
  • USD/JPY

    132.9430
    +0.0700 (+0.05%)
     
  • BTC-USD

    24,549.62
    +1,680.32 (+7.35%)
     
  • CMC Crypto 200

    578.10
    +46.88 (+8.83%)
     
  • FTSE 100

    7,507.11
    +18.96 (+0.25%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

NuVasive Announces Second Quarter 2022 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
·14 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Strong year-over-year net sales growth, driven by new product introductions

Company reiterates full-year guidance range for reported year-over-year net sales growth of 6%–8%

Company updates full-year guidance range for GAAP diluted EPS; maintains prior non-GAAP diluted EPS range provided May 4, 2022

SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2022.

NuVasive Logo
NuVasive Logo

Second Quarter 2022

  • Net sales were $310.5 million, a 5.3% increase as reported and a 7.8% increase on a constant currency basis, compared to the prior year period;

  • GAAP operating margin of 10.7%; Non-GAAP operating margin of 13.0%; and

  • GAAP diluted loss per share of ($0.02); Non-GAAP diluted earnings per share of $0.47.

"We are encouraged by our top-line growth in the second quarter, driven by procedure volumes, new product introductions, and continued global execution of our growth strategies," said Chris Barry, chief executive officer of NuVasive. "As surgeons look for differentiated technologies to enable more intelligent surgery, our C360 portfolio, X360 portfolio and Pulse platform will continue to support our innovation strategy. While we are experiencing the macro environmental pressures that face many companies, we remain focused on our commitment to deliver value to all stakeholders—most importantly, to change the lives of more patients around the world."

Second Quarter 2022 Results
NuVasive reported total net sales of $310.5 million, a 5.3% increase as reported and a 7.8% increase on a constant currency basis, compared to $294.8 million in the prior year period. Second quarter 2022 total net sales were driven by the 2021 commercial launches of the Simplify Cervical Disc and the Pulse platform, as well as higher procedure volume in the U.S. and strong international performance.

For the second quarter of 2022, GAAP gross profit was $224.7 million, compared to $216.5 million in the prior year period. GAAP gross margin was 72.4%, compared to 73.4% in the prior year period. On a non-GAAP basis, gross profit was $224.7 million, compared to $217.1 million in the prior year period. Non-GAAP gross margin was 72.4%, compared to 73.6% in the prior year period.

The Company reported GAAP net loss of ($0.9) million, or diluted loss per share of ($0.02), compared to GAAP net income of $1.8 million, or diluted earnings per share of $0.03 in the prior year period. On a non-GAAP basis, the Company reported net income of $24.8 million, or diluted earnings per share of $0.47, compared to non-GAAP net income of $31.2 million, or diluted earnings per share of $0.60 in the prior year period.

Cash and cash equivalents were $226.0 million as of June 30, 2022.

Full-year 2022 Financial Guidance
Based on the Company's strong performance for the six months ended June 30, 2022, the Company reiterated its full-year guidance range for reported net sales growth. Based on updated expectations for foreign currency exchange rates, the Company revised its guidance range for constant currency net sales growth, as well as for GAAP operating margin, as shown in the table below. In addition, the Company updated its full-year guidance range for GAAP diluted EPS and maintained its prior non-GAAP diluted EPS range provided on May 4, 2022.


Prior guidance range **

Current guidance range **

GAAP

Non-GAAP

GAAP

Non-GAAP

Net sales growth (reported)*

6.0%-8.0%

6.0%-8.0%

6.0%-8.0%

6.0%-8.0%

Net sales growth (constant currency)*


7.5%-9.5%


8.7%-10.7%

Operating margin

6.3%-7.8%

13.0%-14.5%

7.6%-9.1%

13.0%-14.5%

Diluted earnings per share

$1.05-$1.35***

$2.15-$2.45

$0.95-$1.25***

$2.15-$2.45


* Reflects expectations for net sales growth in 2022 compared to 2021. Net sales growth on a constant currency basis excludes year-over-year currency fluctuations, which the Company currently expects to create a negative impact of approximately 270 basis points in 2022.

** Prior guidance reflects ranges provided on May 4, 2022. Current guidance reflects ranges provided on August 3, 2022.

*** Reflects updated expectations for the impact on diluted EPS of applying the if-converted method to the Company's convertible notes. Additionally, includes the impact of net unrealized foreign currency exchange gains or losses incurred as of June 30, 2022, and does not assume future net unrealized gains or losses related to foreign currency exchange rates.


A full reconciliation of GAAP to non-GAAP financial measures can be found in the tables of this press release and in the Investor Relations section of our website.

Conference Call and Webcast
NuVasive will hold a conference call on Wednesday, August 3, 2022, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the second quarter 2022. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call and supplemental financial information of our second quarter 2022 results will be available on the Investor Relations page of our website at www.nuvasive.com. An audio replay of the call will be available until August 10, 2022. The replay dial-in numbers are 1-844-512-2921 for domestic callers and 1-412-317-6671 for international callers. Please use pin number: 13731013. In addition, the webcast will be archived on NuVasive's website.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.

Reconciliation of GAAP to Non-GAAP Information
Management uses certain non-GAAP financial measures such as non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP operating margin, non-GAAP net income (loss), and non-GAAP diluted earnings (loss) per share. These non-GAAP financial measures exclude amortization of intangible assets, business transition costs, purchased in-process research and development, one-time restructuring charges, non-cash purchase accounting adjustments, inventory charges associated with product withdrawals, certain foreign currency impacts and related items in connection with acquisitions, investments and divestitures, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses from strategic investments, gains and losses from changes in fair value of derivatives, non-cash interest expense (excluding debt issuance cost) and other significant one-time items. Management also uses certain non-GAAP measures which are intended to exclude the impact of foreign exchange currency fluctuations. The measure constant currency utilizes an exchange rate that eliminates fluctuations when calculating financial performance numbers. The Company also uses measures such as free cash flow, which represents cash flow from operations less cash used in the acquisition and disposition of capital. Additionally, the Company uses an adjusted EBITDA measure which represents earnings before interest, taxes, depreciation and amortization and excludes the impact of stock-based compensation, business transition costs, purchased in-process research and development, one-time restructuring charges, non-cash purchase accounting adjustments, inventory charges associated with product withdrawals, certain foreign currency impacts and related items in connection with acquisitions, investments and divestitures, certain litigation expenses and settlements, certain European medical device regulation costs, gains and losses on strategic investments, gains and losses from changes in fair value of derivatives and other significant one-time items.

Management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to further and more consistently analyze the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies. Set forth below in the financial tables accompanying this press release are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measure.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release or made on the investor conference call referenced herein that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. In addition, this news release contains selected financial results from the second quarter 2022, as well as projections for 2022 financial guidance and expectations regarding longer-term financial performance. The Company's results for the second quarter of 2022 are prior to the completion of review and audit procedures by the Company's external auditors and are subject to adjustment. In addition, the Company's projections for 2022 financial guidance and expectations regarding longer-term financial performance represent initial estimates, and are subject to the risk of being inaccurate because of the preliminary nature of the forecasts, the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, the impact of the COVID-19 pandemic on the Company's business and financial results; the Company's ability to maintain operations to support its customers and patients in the near-term and to capitalize on future growth opportunities; risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties more fully described in the Company's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

NuVasive, Inc. 

Consolidated Statements of Operations 

(in thousands, except per share data)












Three Months Ended June 30,


Six Months Ended June 30,

(unaudited)


2022


2021


2022


2021

Net sales:









Products


$    280,419


$    266,763


$    546,392


$    512,214

Services


30,032


28,065


54,821


53,863

Total net sales


310,451


294,828


601,213


566,077

Cost of sales (excluding below amortization of intangible assets):









Products


65,267


58,584


122,450


111,886

Services


20,491


19,696


42,405


38,205

Total cost of sales


85,758


78,280


164,855


150,091

Gross profit


224,693


216,548


436,358


415,986

Operating expenses:









Selling, general and administrative


160,696


157,397


320,977


303,351

Research and development


25,913


21,764


49,271


43,988

Amortization of intangible assets


12,637


15,088


25,669


28,425

Business transition costs


(7,624)


11,553


(4,564)


17,137

Total operating expenses


191,622


205,802


391,353


392,901

Interest and other expense, net:









Interest income


262


9


305


96

Interest expense


(4,352)


(4,388)


(8,731)


(12,418)

Other (expense) income, net


(29,681)


1,269


(13,437)


(11,257)

Total interest and other expense, net


(33,771)


(3,110)


(21,863)


(23,579)

(Loss) income before income taxes


(700)


7,636


23,142


(494)

Income tax expense


(193)


(5,837)


(4,834)


(5,217)

Consolidated net (loss) income


$         (893)


$        1,799


$      18,308


$      (5,711)










Net (loss) income per share:









Basic


$        (0.02)


$          0.03


$          0.35


$        (0.11)

Diluted


$        (0.02)


$          0.03


$          0.35


$        (0.11)

Weighted average shares outstanding:









Basic


52,022


51,567


51,926


51,473

Diluted


52,022


52,211


57,299


51,473

 

NuVasive, Inc. 

Consolidated Balance Sheets 

(in thousands, except par value data) 








June 30, 2022


December 31, 2021

ASSETS


(Unaudited)



Current assets:





Cash and cash equivalents


$       225,985


$                246,091

Accounts receivable, net of allowances of $19,166 and $21,064, respectively


233,573


214,398

Inventory, net


331,708


315,845

Prepaid income taxes


5,232


5,425

Prepaid expenses and other current assets


26,812


20,665

Total current assets


823,310


802,424

Property and equipment, net


326,484


303,664

Intangible assets, net


208,323


242,675

Goodwill


629,889


633,467

Operating lease right-of-use assets


98,547


102,987

Deferred tax assets


61,115


48,003

Restricted cash and investments


1,494


1,494

Other assets


25,026


19,361

Total assets


$    2,174,188


$             2,154,075

LIABILITIES AND EQUITY





Current liabilities:





Accounts payable and accrued liabilities


$       123,780


$                115,614

Contingent consideration liabilities


60,292


7,986

Accrued payroll and related expenses


60,284


66,596

Operating lease liabilities


10,298


9,867

Income tax liabilities


959


828

Senior convertible notes


445,745


-

Total current liabilities


701,358


200,891

Long-term senior convertible notes


442,864


884,984

Deferred tax liabilities


11,716


3,049

Operating lease liabilities


106,685


111,592

Contingent consideration liabilities


70,649


139,824

Other long-term liabilities


14,347


18,528

Commitments and contingencies





Stockholders' equity:





Preferred stock, $0.001 par value; 5,000 shares authorized, none outstanding



Common stock, $0.001 par value; 150,000 shares authorized at June 30, 2022 and December 31, 2021; 58,863 shares issued and 52,061 outstanding at June 30, 2022; 58,469 shares issued and 51,769 outstanding at December 31, 2021


63


63

Additional paid-in capital


1,453,013


1,434,976

Accumulated other comprehensive loss


(7,210)


(7,792)

Retained earnings


64,016


45,708

Treasury stock at cost; 6,802 shares and 6,700 shares at June 30, 2022 and December 31, 2021, respectively


(683,313)


(677,748)

Total equity


826,569


795,207

Total liabilities and equity


$    2,174,188


$             2,154,075

 

NuVasive, Inc. 

Consolidated Statements of Cash Flows 

(in thousands) 








Six Months Ended June 30,

(unaudited)


2022


2021

Operating activities:





Consolidated net income (loss)


$   18,308


$   (5,711)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:





Depreciation and amortization


73,285


73,954

Deferred income taxes


(5,304)


(2,942)

Amortization of non-cash interest


3,932


4,721

Stock-based compensation


14,321


13,007

Changes in fair value of contingent consideration


(8,836)


5,957

Net loss (gain) on strategic investments


232


(2,101)

Net loss from foreign currency adjustments


13,574


13,402

Reserves on current assets


(1,461)


8,716

Other non-cash adjustments


8,231


7,249

Changes in operating assets and liabilities, net of effects from acquisitions:





Accounts receivable


(22,596)


(11,541)

Inventory


(14,632)


(20,442)

Prepaid expenses and other current assets


(111)


(1,589)

Accounts payable and accrued liabilities


(6,057)


(5,244)

Accrued payroll and related expenses


(5,207)


1,902

Income taxes


413


58

Net cash provided by operating activities


68,092


79,396

Investing activities:





Acquisition of Simplify Medical, net of cash acquired



(149,463)

Payment of contingent consideration for Simplify Medical



(45,850)

Acquisitions and investments


(5,250)


(500)

Purchases of intangible assets



(1,200)

Purchases of property and equipment


(68,745)


(53,483)

Proceeds from sales of marketable securities



127,023

Proceeds from maturities of marketable securities



46,000

Other investing activities


(698)


180

Net cash used in investing activities


(74,693)


(77,293)

Financing activities:





Payment of contingent consideration


(6,839)


(3)

Proceeds from the issuance of common stock


3,716


3,803

Purchases of treasury stock


(5,565)


(6,964)

Payments upon settlement of senior convertible notes



(649,426)

Other financing activities


(982)


(671)

Net cash used in financing activities


(9,670)


(653,261)

Effect of exchange rate changes on cash


(3,835)


(1,573)

Decrease in cash, cash equivalents and restricted cash


(20,106)


(652,731)

Cash, cash equivalents and restricted cash at beginning of period


247,585


858,363

Cash, cash equivalents and restricted cash at end of period


$ 227,479


$ 205,632

 


For the Three Months Ended June 30, 2022


Reconciliation of GAAP to Non-GAAP Financial Measures


(Unaudited - in thousands, except per share data)











Gross Profit

Operating Profit

Net (Loss) Income

Diluted EPS

Diluted WASO6

Net (Loss) to
Adjusted EBITDA


Reported GAAP

$      224,693

$    33,071

$           (893)

$ (0.02)

52,022

$                      (893)


% of net sales

72.4 %

10.7 %






Amortization of intangible assets


12,637

12,637





Litigation related expenses and settlements1


(353)

(353)